Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences

Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences

Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia, bipolar disorders and other psychotic disorders. However, they might cause metabolic syndrome (MetS) in terms of weight gain, dyslipidemia, type 2 diabetes (T2D), and high blood pressure, which are responsible...

Full description

Bibliographic Details
Main Authors: Marco Carli, Shivakumar Kolachalam, Biancamaria Longoni, Anna Pintaudi, Marco Baldini, Stefano Aringhieri, Irene Fasciani, Paolo Annibale, Roberto Maggio, Marco Scarselli
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Pharmaceuticals
Subjects:
atypical antipsychotics (AAPs)
G protein-coupled receptors (GPCRs)
metabolic syndrome (MetS)
weight gain
type 2 diabetes
dyslipidemia
Online Access:https://www.mdpi.com/1424-8247/14/3/238

Similar Items

Similar Items